CAMBRIDGE, Mass., August 10, 2021 – Today, DoubleRainbow Biosciences, a sustainable health care company harnessing the power of natural evolution through bioengineering to improve the quality of human health, announced a new $10 million investment from Betta Pharmaceuticals as part of the organization’s Series B funding round. The company has raised $26 million to date, with plans to use financing to accelerate compounds into clinical development, grow the organization’s bioceutical division, and expand critical R&D and clinical operations teams.
“Our proprietary platforms allow us to access nature’s astonishing array of therapeutic compounds to bring novel therapeutics and bioceuticals to the world at scale without harming the environment,” said Jing-Ke Weng, Ph.D., Co-founder of Double Rainbow.
